Ceryvyn Therapeutics Ltd
OPT
Hisse Senetlerindeki Sıralama
#31857
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Hisse Fiyatı
$0.00846342
Son senkronizasyon: 2026-07-27
Piyasa Değeri
$11.27M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-99.75%
Ülke
AU
Ticaret Ceryvyn Therapeutics Ltd (OPT)
Kategori
Healthcare
Ceryvyn Therapeutics Ltd (OPT) için gelir
Jun 2025 itibarıyla gelir TTM: $146.02K
Ceryvyn Therapeutics Ltd şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $146.02K'dir. 2024 yılında şirketin geliri $124.67K önceki yıla göre azalma 2023 yılındaki $161.16K gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Ceryvyn Therapeutics Ltd için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $146.02K | 478.27% |
| 2025 | $25.25K | -79.75% |
| 2024 | $124.67K | -22.65% |
| 2023 | $161.16K | 28.88% |
| 2022 | $125.05K | 35.95% |
| 2021 | $91.98K | -8.63% |
| 2020 | $100.67K | 27.42% |
| 2019 | $79.01K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | -100.00% |
| 2008 | $13.77K | -15.24% |
| 2007 | $16.24K | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $10.15K | 19.47% |
| 2004 | $8.50K | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 8,645,674.12% |
US
|
|
| $2.23B | 1,525,749.73% |
US
|
|
| $15.74B | 10,782,430.21% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 4,123,589.23% |
NL
|
